氣派科技(688216.SH):擬投設控股子公司氣派芯競 以開展晶圓測試業務
格隆匯6月16日丨氣派科技(688216.SH)公佈,為進一步提高公司綜合競爭實力,完善公司在集成電路封裝測試的產業佈局,充分發揮自身已有的集成電路成品測試稟賦,擬開展集成電路產業封裝中的前端工序晶圓測試業務,公司與自然人張巧珍合計出資5000.00萬元人民幣設立氣派芯競科技有限公司(簡稱“氣派芯競”)。其中,公司出資4950.00萬元。
氣派芯競以1650.00萬元的價格受讓東莞市譯芯半導體有限公司(簡稱“譯芯半導體”)的晶圓測試設備及其配套測試程序等,譯芯半導體同意由其運營團隊協助完成本次受讓設備的安裝、調試,且在前期提供技術及生產運營支持,同時譯芯半導體也將協助將其現有客户資源導入至氣派芯競。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.